Nicholaos C Bellos MD FIDSA FACP (He/Him)
Medical Director Diagnostic Services Quest Laboratories
Join to View Full Profile
2603 Oak Lawn AveSte 500Dallas, TX 75219
Phone+1 214-396-4201
Fax+1 469-453-3335
Dr. Bellos is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Miami/Jackson Health SystemFellowship, Infectious Disease, 1987 - 1989
Tulane UniversityResidency, Internal Medicine, 1983 - 1987
Baylor College of MedicineClass of 1981
Certifications & Licensure
TX State Medical License 1982 - 2026
FL State Medical License 1987 - 2025
OK State Medical License 2014 - 2015
LA State Medical License 1984 - 1987
American Board of Internal Medicine Internal Medicine
Clinical Trials
- BLADE: Comparison of Once Daily Lopinavir/Ritonavir to Lopinavir/Ritonavir BID Dosing in HIV-Infected Subjects
- Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus Start of enrollment: 2007 Jul 01
- Study of Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in ART-Naive & First Switch Patients Start of enrollment: 2012 Jul 01
Publications & Presentations
PubMed
- 64 citationsBrief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppre...François Raffi, Chloe Orkin, Amanda Clarke, Laurence Slama, Joel E. Gallant
Journal of Acquired Immune Deficiency Syndromes. 2017-06-01 - 24 citationsARIES 144 Week Results: Durable Virologic Suppression in HIV-Infected Patients Simplified to Unboosted Atazanavir/Abacavir/LamivudineKathleen Squires, Benjamin Young, Edwin DeJesus, Nicholaos C. Bellos, Daniel Murphy
HIV Clinical Trials. 2012-09-01 - 5 citationsSimilar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.Daniel J. Skiest, Calvin J. Cohen, Karam Mounzer, Zach Haigney, David Barker
HIV Clinical Trials. 2011-05-01
Professional Memberships
- Infectious Diseases Society of AmericaFellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
